ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2020
Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2).
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Application of IL-17A Inhibitors in Psoriasis Complicated by Multiple Infections - Successful Treatment and Insights from a Case of Psoriasis with HIV and Neurosyphilis.Acta dermato-venereologica · 2026Article
- Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series.Frontiers in medicine · 2026Article
- The invisible agitators: exploring the viral interplay in psoriatic immune dysregulation.Immunologic research · 2025Review
- Psoriasis.Nature reviews. Disease primers · 2025Review
- Infection Risk and Vaccination in the Management of Psoriasis: Considerations for Biologic Therapy.Psoriasis (Auckland, N.Z.) · 2025Review
- Recent Advances in Inflammatory Skin Diseases: Future Research on Viral Reactivations and Vaccine Improvement.Journal of clinical medicine · 2024Article
- The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review.JAAD international · 2024Review
- Psoriasis Flare Following Paramyxovirus Infection.Psoriasis (Auckland, N.Z.) · 2024Article
- Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.Dermatology and therapy · 2023Article
- A gene regulatory network approach harmonizes genetic and epigenetic signals and reveals repurposable drug candidates for multiple sclerosis.Human molecular genetics · 2023Article
- Management of Infections in Psoriatic Patients Treated with Systemic Therapies: A Lesson from the Immunopathogenesis of Psoriasis.Dermatology practical & conceptual · 2023Review
- Apremilast in Psoriasis Patients With Serious Comorbidities: a Case Series and Systematic Review of Literature.Dermatology practical & conceptual · 2022Review
- A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project.Dermatology reports · 2022Article
- Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.Dermatology and therapy · 2022Article
- Therapeutic challenges of psoriasis in the HIV-infected patient: A case report.Experimental and therapeutic medicine · 2022Article
- Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2021Review
- Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware of the effects of systemic treatments not only on psoriasis but also on co-occurring diseases. In case of other coexisting inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders, some treatments have to be avoided as they may be harmful.
objectiveThe primary objective of this project was to collect evidence for the creation of practice guidelines for systemic treatment of psoriasis (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis).
methodsEvidence-based recommendations were formulated using a quasi-Delphi methodology after a systematic search of the literature and a consensus procedure involving eight psoriasis experts.
resultsRecommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel disease, demyelinating disorders, hepatitis B and C, HIV and cancer.
conclusionThis expert opinion is a practical guide for dermatologists when handling psoriasis patients with these specific conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.